What could change its growth trajectory, and what would confirm it?
The pharmaceutical segment's recurring revenue is what BactiQuant must keep growing, since that increase mainly powered its 36 percent revenue rise in the first nine months over the same period in 2025.
BactiQuant directs its sales efforts at pharmaceuticals, water treatment and aquaculture worldwide, backed by a sales organization it recently expanded. The company is pursuing cash-neutral operations and EBITDA break-even, with remaining issue proceeds supplying fresh growth capital; those proceeds fully covered repayment of the DKK 7.2 million EIFO loan redeemed on September 30, 2026. After that settlement BactiQuant is completely debt-free, and annual liquidity improves by DKK 2.2 million.
Which risks could break the thesis, and what would warn of them?
BactiQuant grew primarily on increased recurring revenue in the pharmaceutical segment, while the capital behind that growth comes from a share issue subscribed by eight investors—executive management, the Chairman of the Board, existing shareholders, and two new investors—that dilutes existing shareholders who did not participate by approximately 9.93%.
The remaining proceeds fund cash-neutral operations and EBITDA break-even, fully repay the DKK 7.2 million EIFO loan redeemed on September 30, 2026, leave BactiQuant completely debt-free with annual liquidity improved by DKK 2.2 million, and strengthen the financial position while reducing ongoing financing costs.
What does the product do for its buyer, and how is it delivered?
BactiQuant measures a naturally occurring enzyme activity of predominantly bacterial origin by reacting a fluorescence-labelled enzyme substrate that releases a soluble fluorophore, which is extracted and quantified by fluorometry, so buyers can test industrial wastewater, potable water, saline water and pharmaceutical purified water with one assay.
BactiQuant offers BQ 100 for water utilities and industrial applications, covering potable water and complex process water, and BQ 200 for pharmaceutical applications covering purified water and water for injection. BactiQuant Online integrates with existing GSM/SCADA systems, and the handheld technology supports grab-sample strategies, troubleshooting, pollution tracking and emergency response.

BactiQuant provides near-real-time bacterial monitoring and total bacteria quantification for water.